曲妥珠单抗联合依维莫司新辅助治疗早期HER2阳性乳腺癌的II期随机研究
RADHER试验将82例早期可手术HER2阳性乳腺癌患者1:1随机分配接受术前曲妥珠单抗单药或联合依维莫司治疗,主要终点为6周临床缓解率。结果显示联合组临床缓解率43.9%对34.1%,病理缓解率47.5%对43.6%,但毒性增加;PIK3CA突变预测曲妥珠单抗耐药,联合治疗诱导MAPK通路信号改变。
要点
- 加用依维莫司未显著改善临床或病理缓解率
- 联合组口腔黏膜炎和皮疹发生率明显增加但III/IV级罕见
- PIK3CA突变预测曲妥珠单抗耐药,联合治疗诱导MAPK通路活化
核心结论
- 加用依维莫司未改善疗效但诱导MAPK信号通路活化,提示需联合阻断通路交叉对话以最大化曲妥珠单抗疗效。
研究设计与样本
- II期随机研究,82例早期可手术HER2阳性乳腺癌患者1:1随机接受术前曲妥珠单抗单药或联合依维莫司治疗。
- 曲妥珠单抗首剂4 mg/kg后每周2 mg/kg共5周;依维莫司10 mg/天共6周,随后手术。
- 主要终点为6周临床缓解率,同时评估病理缓解和安全性,并对基线及手术样本进行免疫组化和多重免疫分析。
主要发现
- 曲妥珠单抗单药组与联合依维莫司组的临床缓解率分别为34.1%和43.9%。
- 两组的病理缓解率分别为43.6%和47.5%。
- 联合依维莫司增加毒性,口腔黏膜炎发生率82.5%对5.0%,皮疹57.5%对10.0%,但III/IV级事件罕见。
- 除PIK3CA突变预测曲妥珠单抗耐药外,未发现基线候选生物标志物与治疗缓解相关。
- 联合治疗后观察到多个MAPK通路效应分子的显著变化。
关键数值与推荐
- 临床缓解率:曲妥珠单抗单药34.1%,联合依维莫司43.9%。
- 病理缓解率:曲妥珠单抗单药43.6%,联合依维莫司47.5%。
- 口腔黏膜炎发生率:联合组82.5%,单药组5.0%;皮疹发生率:联合组57.5%,单药组10.0%。
临床怎么用
- 在早期HER2阳性乳腺癌新辅助治疗中,不推荐常规加用依维莫司,因疗效未改善且毒性增加。
- PIK3CA突变状态可能有助于识别曲妥珠单抗耐药患者。
- 针对MAPK通路交叉对话的联合策略值得进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Resistance to trastuzumab in breast cancer is an ongoing challenge. Clinical and biological effects of co-targeting HER2 and mammalian target of rapamycin (mTOR) in patients with HER2-positive early operable breast cancer via the addition of everolimus to preoperative trastuzumab were evaluated in a phase II randomised study. METHODS: Patients were randomised 1:1 to receive trastuzumab (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks) alone or combined with everolimus (10 mg/day for 6 weeks) and then underwent surgery. Tumours were assessed by clinical examination and echography at the baseline and on treatment. The primary end-point was the clinical response rate at 6 weeks. Pathological response and safety were also evaluated. Baseline and surgery tumour samples were assessed by immunohistochemistry and multiplex immunoanalysis for predictive downstream effectors of the PI3K/AKT/mTOR and MAP kinase (MAPK) pathways. RESULTS: Eighty-two patients were enrolled, 41 per arm. The clinical response rates were 34.1% and 43.9% with trastuzumab alone and combined with everolimus, respectively. Pathological response rates were 43.6% and 47.5%, respectively. Addition of everolimus increased toxicity, notably mucositis (82.5% versus 5.0%) and rash (57.5% versus 10.0%), but grade III/IV events were rare. No correlation between response to treatments and baseline candidate biomarkers was identified, except for PIK3CA mutations which were found to predict trastuzumab resistance. Significant changes were seen in several MAPK pathway effectors after combination therapy. CONCLUSIONS: The addition of everolimus did not improve the efficacy, but induced MAPK signalling. Combination therapy to overcome pathway cross-talk should be considered to maximise the effectiveness of trastuzumab in this setting. ClinicalTrial.gov Identifier NCT00674414.
引用
- Campone M, Bachelot T, Treilleux I, et al. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). Eur J Cancer. 2021. PMID: 34678678. doi:10.1016/j.ejca.2021.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。